Trial
NCT04737330
A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED)
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
Thyroid Eye Disease
Intervention
Secukinumab
Why stopped
Analysis of blinded patient data showed a very low probability of the study meeting the primary efficacy endpoints. No safety concerns were identified
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-04-15